Inmagene receives FDA clearance for Phase I trial of immunological disease BTK inhibitor asset
A small molecule BTK inhibitor, IMG-004 is being developed to potentially treat immunological diseases.
Immunology
Latest in
Immunology
Intrommune previews Phase II trial design for peanut allergy toothpaste
Intrommune CEO Michael Nelson details plans for a Phase II trial in children with peanut allergies slated for late 2022…
By
AAD 2022: patient-reported outcomes key for atopic dermatitis product messaging
Dupixent (dupilumab) is expected to maintain its market advantage for moderate-to-severe atopic dermatitis despite competition.
By
Equillium begins Phase III acute graft-versus-host disease trial
The trial will have 200 adult and adolescent subjects with Grade III-IV aGVHD, or Grade II aGVHD with reduced GI…
Discovery of VB HIV variant underscores need for HIV prevention scale-up
The discovery of the VB variant of human immunodeficiency virus (HIV) underscores the need to mitigate the global HIV epidemic.
By
Unlearn.AI, Merck KGaA collaborate to expedite immunology trials
Merck will use Twintelligent RCTs to integrate prognostic information from Digital Twins into its randomised controlled trials.
Immunology Trends: Asthma most mentioned term on Twitter Q4 2021
Clinical Trials Arena lists the top five terms tweeted on immunology in Q4 2021, based on data from GlobalData’s Pharmaceuticals…
Revolo obtains MHRA approval for Phase II autoimmune disease drug trials
One of the trials will enrol moderate-to-severe active rheumatoid arthritis patients.